FDA Clarifies Standards for Clinical Validation of Artificial Intelligence in Medical Software

The U.S. Food and Drug Administration has issued updated guidance on the validation of artificial intelligence and machine learning software classified as medical devices. The documents stress a lifecycle approach that covers development, premarket review, and postmarket monitoring. Manufacturers must now provide detailed plans for handling future algorithm modifications and collect real-world performance data.

What this means

The guidance expands documentation requirements for premarket submissions and ties them to ongoing evidence collection after devices reach the market. It links validation practices to principles developed with international partners. Regulators expect transparent reporting of clinical performance metrics throughout a product's use.

Key takeaways

• The FDA's 2021 action plan calls for continuous performance monitoring and risk management across the full device lifecycle [1].
• Draft guidance from 2023 requires algorithm change protocols that describe planned modifications, performance checks, and revalidation steps in premarket filings [2].
• Good Machine Learning Practice principles, endorsed in 2021 with Health Canada, MHRA, and IMDRF partners, form the foundation for development and validation activities [3].
• Clinical evidence must support initial safety and effectiveness claims while protocols for postmarket surveillance remain active [1].
• Some recommendations stay in draft form and may shift after public comment periods close.

Lifecycle validation requirements

The action plan directs sponsors to treat AI/ML software as a total product rather than a one-time submission. Sponsors demonstrate safety through repeated assessments that track how models perform on new data. Real-world evidence collection supports these repeated checks.

Algorithm change protocols

The 2023 draft guidance introduces predetermined change control plans. These plans list specific modifications a manufacturer anticipates, the methods used to test each change, and the thresholds that trigger additional regulatory review. Documentation must cover both minor updates and more substantial retraining events.

Clinical evidence and transparency

Sponsors submit clinical performance data that reflect intended use populations and settings. The guidance asks for clear metrics on accuracy, robustness, and equity across subgroups. Postmarket reports then compare these metrics against observed outcomes in routine care.

Alignment with international standards

The good machine learning practice document reflects joint work among the FDA, Health Canada, the UK's MHRA, and the International Medical Device Regulators Forum. Shared principles cover data quality, model training practices, and human oversight. Global manufacturers can reference this alignment when preparing submissions for multiple jurisdictions.

Limitations

The 2023 guidance remains in draft and subject to revision. International standards continue to evolve, which may create differing compliance paths for firms operating in several regions. Current documents do not address every possible AI/ML architecture or clinical use case.

Last updated: September 7, 2026